Skip to main content
. 2016 Jun 28;4(12):e12841. doi: 10.14814/phy2.12841

Figure 2.

Figure 2

Cell composition of the neointima after patch venoplasty. (A) Representative Western blot showing expression of CD34, VEGFR2, α‐actin, CD68, CD45, vimentin and GAPDH in the control IVC (vein), preimplantation patch (day 0), and neointima at day 7 or 30; n = 3. (B) Immunofluorescence analysis of the neointima at days 7 or 30 and control IVC (vein). Upper row, merge of CD34 (green), VEGFR2 (red), and DAPI (blue). Lower row, merge of CD34 (green), α‐actin (red), and DAPI (blue); scale bar, 50 μm; L, lumen; N, neointima; yellow arrow shows colocalization; n = 4. (C) Immunohistochemical analysis of the neointima at day 0 (upper row), day 7 (center row), or day 30 (lower row). Day 0 (upper row) shows control preimplantation patch without neointima. Analysis for: first column, CD31; second column, α‐actin; third column, CD68; fourth column, CD45; fifth column, vimentin. P, patch; L, lumen; N, neointima; yellow arrows show the positive cells. Scale bar, 100 μm; n = 4. (D) Bar graph showing endothelial confluence; P < 0.0001, ANOVA. *P < 0.0001 versus day 0; **P = 0.0048 versus day 7 (post hoc test); n = 4. (E) Bar graph showing the mean neointimal smooth muscle cell (SMC) density; P < 0.0001, ANOVA. *P < 0.0001 versus day 0 (post hoc test); n = 4. (F–H) Bar graphs showing percentage of neointimal CD45, CD68 and vimentin positive cells(mean number of cells counted in 4 high power fields); P < 0.0001, ANOVA). *P < 0.0001 versus day 0; **P < 0.01 versus day 7 (post hoc test); n = 4.